Latest News

Donanemab FDA AdComm Hearing Scheduled for June 10, Eli Lilly Says
Donanemab FDA AdComm Hearing Scheduled for June 10, Eli Lilly Says

May 8th 2024

The AdComm plans to review data from the TRAILBLAZER-ALZ 2 phase 3 clinical trial that served as the foundation for Eli Lilly's original BLA submission to the FDA.

Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Regulatory Submission  / image credit obese man asleep / ©motortion/stock.adobe.com
Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission

April 17th 2024

AbbVie Announces Late Breaking Data at AAN to Support Atogepant Long-Term Safety, Efficacy for Migraine Prevention / image credit head pain ©jiris/stock.adobe.com
AbbVie Announces Late Breaking Data at AAN to Support Atogepant Long-Term Safety, Efficacy for Migraine Prevention

April 12th 2024

Consider CGRP Inhibitors as a First-Line Option for Preventive Treatment of Migraine: New American Headache Society Consensus Statement / image credit - headache: ©peterschreiber.media/stock.adobe.com
Consider CGRP Inhibitors as a First-Line Option for Preventive Treatment of Migraine: New American Headache Society Consensus Statement

April 12th 2024

Atogepant vs Rimegepant for Migraine Prevention: Daily Dose / image credit: ©New Africa/AdobeStock
Atogepant vs Rimegepant for Migraine Prevention: Daily Dose

April 11th 2024

Video Interviews
Podcasts
Latest CME Events & Activities

Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data

View More

Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis

View More

Facing the Challenges of Implementing Palliative Care

View More

Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

September 15, 2024

Register Now!

Mastering MS: Translating Evidence into Optimal Management Plans

View More

Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care

View More

Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes

View More

5th Annual International Congress on the Future of Neurology®

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

Burst CME: Optimizing Therapy in Parkinson’s Disease

View More

Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders

View More

Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders

View More

Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis

View More

Individualizing Treatment for Patients with Generalized Myasthenia Gravis

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care

View More

Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations

View More

More News

© 2024 MJH Life Sciences

All rights reserved.